Retatrutide is a peptide, distinguished as a triple agonist because it activates three metabolic hormone receptors: GLP-1, GIP, and Glucagon. This mechanism has resulted in unprecedented efficacy in clinical trials, where participants achieved average weight loss nearing 29% and experienced significant improvements in metabolic health markers and conditions like knee osteoarthritis. Given the success of the ongoing TRIUMPH trial program, which has seven additional readouts expected in 2026, industry analysts project that Retatrutide could potentially receive FDA approval in 2027, establishing it as one of the most powerful treatments for obesity and related complications.
